2hwo Citations

Structure-guided development of affinity probes for tyrosine kinases using chemical genetics.

Nat. Chem. Biol. 3 229-38 (2007)
Related entries: 2j5f, 2j5e, 2hwp

Cited: 65 times
EuropePMC logo PMID: 17334377


As key components in nearly every signal transduction pathway, protein kinases are attractive targets for the regulation of cellular signaling by small-molecule inhibitors. We report the structure-guided development of 6-acrylamido-4-anilinoquinazoline irreversible kinase inhibitors that potently and selectively target rationally designed kinases bearing two selectivity elements that are not found together in any wild-type kinase: an electrophile-targeted cysteine residue and a glycine gatekeeper residue. Cocrystal structures of two irreversible quinazoline inhibitors bound to either epidermal growth factor receptor (EGFR) or engineered c-Src show covalent inhibitor binding to the targeted cysteine (Cys797 in EGFR and Cys345 in engineered c-Src). To accommodate the new covalent bond, the quinazoline core adopts positions that are different from those seen in kinase structures with reversible quinazoline inhibitors. Based on these structures, we developed a fluorescent 6-acrylamido-4-anilinoquinazoline affinity probe to report the fraction of kinase necessary for cellular signaling, and we used these reagents to quantitate the relationship between EGFR stimulation by EGF and its downstream outputs-Akt, Erk1 and Erk2.

Articles - 2hwo mentioned but not cited (1)

Reviews citing this publication (14)

  1. Cheminfomatic-based Drug Discovery of Human Tyrosine Kinase Inhibitors. Reid TE, Fortunak JM, Wutoh A, Simon Wang X. Curr Top Med Chem 16 1452-1462 (2016)
  2. Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors. Juchum M, Günther M, Laufer SA. Drug Resist. Updat. 20 12-28 (2015)
  3. Epidermal growth factor receptor inhibitors: a patent review (2010 - present). Li SN, Li HQ. Expert Opin Ther Pat 24 309-321 (2014)
  4. Enzyme inhibitor discovery by activity-based protein profiling. Niphakis MJ, Cravatt BF. Annu. Rev. Biochem. 83 341-377 (2014)
  5. New approaches for dissecting protease functions to improve probe development and drug discovery. Deu E, Verdoes M, Bogyo M. Nat. Struct. Mol. Biol. 19 9-16 (2012)
  6. Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer. Carmi C, Mor M, Petronini PG, Alfieri RR. Biochem. Pharmacol. 84 1388-1399 (2012)
  7. Nanoparticles for cancer therapy using magnetic forces. Tietze R, Lyer S, Dürr S, Alexiou C. Nanomedicine (Lond) 7 447-457 (2012)
  8. Activity-based probes: discovering new biology and new drug targets. Heal WP, Dang TH, Tate EW. Chem Soc Rev 40 246-257 (2011)
  9. Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. Haan C, Behrmann I, Haan S. J. Cell. Mol. Med. 14 504-527 (2010)
  10. Calcium-dependent signaling and kinases in apicomplexan parasites. Billker O, Lourido S, Sibley LD. Cell Host Microbe 5 612-622 (2009)
  11. Activity-based protein profiling: from enzyme chemistry to proteomic chemistry. Cravatt BF, Wright AT, Kozarich JW. Annu. Rev. Biochem. 77 383-414 (2008)
  12. Structure and clinical relevance of the epidermal growth factor receptor in human cancer. Kumar A, Petri ET, Halmos B, Boggon TJ. J. Clin. Oncol. 26 1742-1751 (2008)
  13. The development of HKI-272 and related compounds for the treatment of cancer. Wissner A, Mansour TS. Arch. Pharm. (Weinheim) 341 465-477 (2008)
  14. Activity-based probes as a tool for functional proteomic analysis of proteases. Fonović M, Bogyo M. Expert Rev Proteomics 5 721-730 (2008)

Articles citing this publication (50)

  1. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N. Nature 464 427-430 (2010)
  2. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Yap DB, Chu J, Berg T, Schapira M, Cheng SW, Moradian A, Morin RD, Mungall AJ, Meissner B, Boyle M, Marquez VE, Marra MA, Gascoyne RD, Humphries RK, Arrowsmith CH, Morin GB, Aparicio SA. Blood 117 2451-2459 (2011)
  3. Reversible inhibitor of p97, DBeQ, impairs both ubiquitin-dependent and autophagic protein clearance pathways. Chou TF, Brown SJ, Minond D, Nordin BE, Li K, Jones AC, Chase P, Porubsky PR, Stoltz BM, Schoenen FJ, Patricelli MP, Hodder P, Rosen H, Deshaies RJ. Proc. Natl. Acad. Sci. U.S.A. 108 4834-4839 (2011)
  4. Calcium-dependent protein kinase 1 is an essential regulator of exocytosis in Toxoplasma. Lourido S, Shuman J, Zhang C, Shokat KM, Hui R, Sibley LD. Nature 465 359-362 (2010)
  5. Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. Johnson DS, Weerapana E, Cravatt BF. Future Med Chem 2 949-964 (2010)
  6. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Fan QW, Cheng CK, Gustafson WC, Charron E, Zipper P, Wong RA, Chen J, Lau J, Knobbe-Thomsen C, Weller M, Jura N, Reifenberger G, Shokat KM, Weiss WA. Cancer Cell 24 438-449 (2013)
  7. Drug discovery using chemical systems biology: weak inhibition of multiple kinases may contribute to the anti-cancer effect of nelfinavir. Xie L, Evangelidis T, Xie L, Bourne PE. PLoS Comput. Biol. 7 e1002037 (2011)
  8. A coupled chemical-genetic and bioinformatic approach to Polo-like kinase pathway exploration. Snead JL, Sullivan M, Lowery DM, Cohen MS, Zhang C, Randle DH, Taunton J, Yaffe MB, Morgan DO, Shokat KM. Chem. Biol. 14 1261-1272 (2007)
  9. A road map to evaluate the proteome-wide selectivity of covalent kinase inhibitors. Lanning BR, Whitby LR, Dix MM, Douhan J, Gilbert AM, Hett EC, Johnson TO, Joslyn C, Kath JC, Niessen S, Roberts LR, Schnute ME, Wang C, Hulce JJ, Wei B, Whiteley LO, Hayward MM, Cravatt BF. Nat. Chem. Biol. 10 760-767 (2014)
  10. Weighted equation and rules--a novel concept for evaluating protein-ligand interaction. Chen CY. J. Biomol. Struct. Dyn. 27 271-282 (2009)
  11. Structure-activity relationship study reveals ML240 and ML241 as potent and selective inhibitors of p97 ATPase. Chou TF, Li K, Frankowski KJ, Schoenen FJ, Deshaies RJ. ChemMedChem 8 297-312 (2013)
  12. 6-Ethynylthieno[3,2-d]- and 6-ethynylthieno[2,3-d]pyrimidin-4-anilines as tunable covalent modifiers of ErbB kinases. Wood ER, Shewchuk LM, Ellis B, Brignola P, Brashear RL, Caferro TR, Dickerson SH, Dickson HD, Donaldson KH, Gaul M, Griffin RJ, Hassell AM, Keith B, Mullin R, Petrov KG, Reno MJ, Rusnak DW, Tadepalli SM, Ulrich JC, Wagner CD, Vanderwall DE, Waterson AG, Williams JD, White WL, Uehling DE. Proc. Natl. Acad. Sci. U.S.A. 105 2773-2778 (2008)
  13. Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis. Huang D, Zhou T, Lafleur K, Nevado C, Caflisch A. Bioinformatics 26 198-204 (2010)
  14. Mechanism for activation of mutated epidermal growth factor receptors in lung cancer. Red Brewer M, Yun CH, Lai D, Lemmon MA, Eck MJ, Pao W. Proc. Natl. Acad. Sci. U.S.A. 110 E3595-604 (2013)
  15. Kinetics of inhibitor cycling underlie therapeutic disparities between EGFR-driven lung and brain cancers. Barkovich KJ, Hariono S, Garske AL, Zhang J, Blair JA, Fan QW, Shokat KM, Nicolaides T, Weiss WA. Cancer Discov 2 450-457 (2012)
  16. Chemical genetic strategy for targeting protein kinases based on covalent complementarity. Garske AL, Peters U, Cortesi AT, Perez JL, Shokat KM. Proc. Natl. Acad. Sci. U.S.A. 108 15046-15052 (2011)
  17. CovalentDock: automated covalent docking with parameterized covalent linkage energy estimation and molecular geometry constraints. Ouyang X, Zhou S, Su CT, Ge Z, Li R, Kwoh CK. J Comput Chem 34 326-336 (2013)
  18. Selective, rapid and optically switchable regulation of protein function in live mammalian cells. Tsai YH, Essig S, James JR, Lang K, Chin JW. Nat Chem 7 554-561 (2015)
  19. Small molecule probes that target Abl kinase. Kalesh KA, Sim DS, Wang J, Liu K, Lin Q, Yao SQ. Chem. Commun. (Camb.) 46 1118-1120 (2010)
  20. Mechanisms for kinase-mediated dimerization of the epidermal growth factor receptor. Lu C, Mi LZ, Schürpf T, Walz T, Springer TA. J. Biol. Chem. 287 38244-38253 (2012)
  21. Modular synthesis of radicicol A and related resorcylic acid lactones, potent kinase inhibitors. Dakas PY, Barluenga S, Totzke F, Zirrgiebel U, Winssinger N. Angew. Chem. Int. Ed. Engl. 46 6899-6902 (2007)
  22. Characterization of irreversible kinase inhibitors by directly detecting covalent bond formation: a tool for dissecting kinase drug resistance. Klüter S, Simard JR, Rode HB, Grütter C, Pawar V, Raaijmakers HC, Barf TA, Rabiller M, van Otterlo WA, Rauh D. Chembiochem 11 2557-2566 (2010)
  23. Conformational regulation of the EGFR kinase core by the juxtamembrane and C-terminal tail: a molecular dynamics study. Mustafa M, Mirza A, Kannan N. Proteins 79 99-114 (2011)
  24. Coupling protein engineering with probe design to inhibit and image matrix metalloproteinases with controlled specificity. Morell M, Nguyen Duc T, Willis AL, Syed S, Lee J, Deu E, Deng Y, Xiao J, Turk BE, Jessen JR, Weiss SJ, Bogyo M. J. Am. Chem. Soc. 135 9139-9148 (2013)
  25. An improved mechanism-based cross-linker for multiplexed kinase detection and inhibition in a complex proteome. Liu K, Kalesh KA, Ong LB, Yao SQ. Chembiochem 9 1883-1888 (2008)
  26. A coupled protein and probe engineering approach for selective inhibition and activity-based probe labeling of the caspases. Xiao J, Broz P, Puri AW, Deu E, Morell M, Monack DM, Bogyo M. J. Am. Chem. Soc. 135 9130-9138 (2013)
  27. Discovery of boron-conjugated 4-anilinoquinazoline as a prolonged inhibitor of EGFR tyrosine kinase. Ban HS, Usui T, Nabeyama W, Morita H, Fukuzawa K, Nakamura H. Org. Biomol. Chem. 7 4415-4427 (2009)
  28. Traditional Chinese medicine as dual guardians against hypertension and cancer? Tou WI, Chen CY. J. Biomol. Struct. Dyn. 30 299-317 (2012)
  29. Asp-960/Glu-961 controls the movement of the C-terminal tail of the epidermal growth factor receptor to regulate asymmetric dimer formation. Yang KS, Macdonald-Obermann JL, Piwnica-Worms D, Pike LJ. J. Biol. Chem. 285 24014-24022 (2010)
  30. Ibrutinib (ImbruvicaTM) potently inhibits ErbB receptor phosphorylation and cell viability of ErbB2-positive breast cancer cells. Grabinski N, Ewald F. Invest New Drugs 32 1096-1104 (2014)
  31. A computational workflow for the design of irreversible inhibitors of protein kinases. Del Rio A, Sgobba M, Parenti MD, Degliesposti G, Forestiero R, Percivalle C, Conte PF, Freccero M, Rastelli G. J. Comput. Aided Mol. Des. 24 183-194 (2010)
  32. A general approach for the development of fluorogenic probes suitable for no-wash imaging of kinases in live cells. Zhang Q, Liu H, Pan Z. Chem. Commun. (Camb.) 50 15319-15322 (2014)
  33. Structure-functional prediction and analysis of cancer mutation effects in protein kinases. Dixit A, Verkhivker GM. Comput Math Methods Med 2014 653487 (2014)
  34. Synthesis, characterisation, and in vitro anticancer activity of curcumin analogues bearing pyrazole/pyrimidine ring targeting EGFR tyrosine kinase. Ahsan MJ, Khalilullah H, Yasmin S, Jadav SS, Govindasamy J. Biomed Res Int 2013 239354 (2013)
  35. Co-conserved features associated with cis regulation of ErbB tyrosine kinases. Mirza A, Mustafa M, Talevich E, Kannan N. PLoS ONE 5 e14310 (2010)
  36. Synthesis and biological evaluation of p38alpha kinase-targeting dialkynylimidazoles. Li J, Kaoud TS, Laroche C, Dalby KN, Kerwin SM. Bioorg. Med. Chem. Lett. 19 6293-6297 (2009)
  37. In silico identification of EGFR-T790M inhibitors with novel scaffolds: start with extraction of common features. Xiang M, Lei K, Fan W, Lin Y, He G, Yang M, Chen L, Mo Y. Drug Des Devel Ther 7 789-839 (2013)
  38. Synthesis and biological evaluation of 7-substituted-1-(3-bromophenylamino)isoquinoline-4-carbonitriles as inhibitors of myosin light chain kinase and epidermal growth factor receptor. Rode HB, Sos ML, Grütter C, Heynck S, Simard JR, Rauh D. Bioorg. Med. Chem. 19 429-439 (2011)
  39. Combined inhibition of the EGFR/AKT pathways by a novel conjugate of quinazoline with isothiocyanate. Tarozzi A, Marchetti C, Nicolini B, D'Amico M, Ticchi N, Pruccoli L, Tumiatti V, Simoni E, Lodola A, Mor M, Milelli A, Minarini A. Eur J Med Chem 117 283-291 (2016)
  40. Development and Validation of Rapid Stability-Indicating RP-HPLC-DAD Method for the Quantification of Lapatinib and Mass Spectrometry Analysis of Degraded Products. Saadat E, Dehghan Kelishady P, Ravar F, Kobarfard F, Dorkoosh FA. J Chromatogr Sci 53 932-939 (2015)
  41. In silico screening of epidermal growth factor receptor (EGFR) in the tyrosine kinase domain through a medicinal plant compound database. Sawatdichaikul O, Hannongbua S, Sangma C, Wolschann P, Choowongkomon K. J Mol Model 18 1241-1254 (2012)
  42. Design and synthesis of AX4697, a bisindolylmaleimide exo-affinity probe that labels protein kinase C alpha and beta. Liu Y, Wu J, Weissig H, Betancort JM, Gai WZ, Leventhal PS, Patricelli MP, Samii B, Szardenings AK, Shreder KR, Kozarich JW. Bioorg. Med. Chem. Lett. 18 5955-5958 (2008)
  43. Activation of EGFR by small compounds through coupling the generation of hydrogen peroxide to stable dimerization of Cu/Zn SOD1. Sakanyan V, Hulin P, Alves de Sousa R, Silva VA, Hambardzumyan A, Nedellec S, Tomasoni C, Logé C, Pineau C, Roussakis C, Fleury F, Artaud I. Sci Rep 6 21088 (2016)
  44. Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent. Liu W, Ning JF, Meng QW, Hu J, Zhao YB, Liu C, Cai L. Drug Des Devel Ther 9 3837-3851 (2015)
  45. Convergent assembly of structurally diverse quinazolines. Crespo A, Coelho A, Diz PM, Fernández F, Novoa de Armas H, Sotelo E. Org. Biomol. Chem. 9 351-357 (2011)
  46. Kinase clamping. Rusk N. Nat. Methods 4 382-383 (2007)
  47. Targeting the off-targets: a computational bioinformatics approach to understanding the polypharmacology of nelfinavir. Brüning A. Expert Rev Clin Pharmacol 4 571-573 (2011)
  48. Schiff bases of indoline-2,3-dione (isatin) with potential antiproliferative activity. Aboul-Fadl T, Radwan AA, Attia MI, Al-Dhfyan A, Abdel-Aziz HA. Chem Cent J 6 49 (2012)
  49. Synthesis of new spirooxindole-pyrrolothiazole derivatives: Anti-cancer activity and molecular docking. Lotfy G, Said MM, El Ashry ES, El Tamany ES, Al-Dhfyan A, Abdel Aziz YM, Barakat A. Bioorg. Med. Chem. 25 1514-1523 (2017)
  50. Studying the Conformation of a Receptor Tyrosine Kinase in Solution by Inhibitor-Based Spin Labeling. Yin DM, Hannam JS, Schmitz A, Schiemann O, Hagelueken G, Famulok M. Angew. Chem. Int. Ed. Engl. 56 8417-8421 (2017)